Topical difluprednate for the treatment of harada’s disease

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 157-167

  Onishi, Spencer M ^a   Asahi, Masumi G ^a   Chou, Calvin ^a   Gallemore, Ron P ^a  

^a Retina Macula Institute   (United States)

Author keywords

Noninfectious posterior uveitis; Serous retinal detachment; Steroid

Indexed keywords

BRIMONIDINE; BROMFENAC; DIFLUPREDNATE; DORZOLAMIDE PLUS TIMOLOL; LOTEPREDNOL; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE;

ADULT; ARTICLE; BLURRED VISION; CASE REPORT; CASE STUDY; CATARACT; DIABETES MELLITUS; DIPLOPIA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLEXIA; EYE INFLAMMATION; FAMILY HISTORY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LOADING DRUG DOSE; MEDICAL RECORD REVIEW; MIDDLE AGED; NEOPLASM; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PIGMENT EPITHELIUM; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; SUBRETINAL FLUID; VISUAL ACUITY; VISUAL IMPAIRMENT; VOGT KOYANAGI SYNDROME;

EID: 84921725683     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S72955     Document Type: Article

References (15)

1. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46(2):111–122.
2. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–652.
3. Sheppard JD, Toyos MM, Kempen JH, et al. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci. 2014;55(5):2993–3002.
4. Weisz JM, Holland GN, Roer LN, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in Southern California. Ophthalmology. 1995;102(7):1012–1015.
5. Davis JL, Mittal KK, Freidlin V, et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology. 1990;97(9):1137–1142.
6. El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139(2):177–184.
7. Bucolo C, Cuzzocrea S, Mazzon E, et al. Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2003;44(3):1178–1184.
8. Cunha R, Martins RG, Brito H, et al. Posterior subtenon triamcinalone acetonide injection as an adjunctive treatment in patients with recurrent Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci. 2010;51:E-Abstract 5831.
9. Yamaguchi M, Yasueda S, Isowaki A, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm. 2005;301:121–128.
10. Tajika T, Isowaki A, Sakaki H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther. 2011;27(1):43–49.
11. Nakano S, Yamamoto T, Kirii E, Abe S, Yamashita H. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248:805–810.
12. Foster CS, DaVanzo R, Flynn TE, et al. Durezol (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26(5):475–483.
13. Donnenfeld ED. Difluprednate for the prevention of ocular inflammation post surgery: an update. Clin Ophthalmol. 2011;5:811–816.
14. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I, the effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482–491.
15. Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381–390.